Low-grade inflammation, thrombogenicity, and atherogenic lipid profile in cigarette smokers

Circulation Journal

Volumn 70, Issue 1, 2006, Pages 8-13

  Yasue, Hirofumi ^a,c   Hirai, Nobutaka ^b   Mizuno, Yuji ^a   Harada, Eisaku ^a   Itoh, Teruhiko ^a   Yoshimura, Michihiro ^b   Kugiyama, Kiyotaka ^b   Ogawa, Hisao ^b  

^a Kumamoto Kinou Hospital   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c Kumamoto Aging Research Institute   (Japan)

Author keywords

C reactive protein; Dyslipidemia; Inflammation; Smoking; Thrombosis

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DYSLIPIDEMIA; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERCOAGULABILITY; INFLAMMATORY INFILTRATE; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; THROMBOCYTE AGGREGATION; THROMBOGENICITY; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BLOOD CELL COUNT; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; REFERENCE VALUES; SMOKING; SMOKING CESSATION;

EID: 29644436026     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.8     Document Type: Article

References (50)

1. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: A statement for healthcare professionals from the American Heart Association (American Heart Association Task Force on Risk Reduction). Circulation 1997; 96: 3243-3247.
2. Takaoka K, Yoshimura M, Ogawa H, Kugiyama K, Nakayama M, Yasue H. Comparison of the risk factors for coronary artery spasm with those for organic stenosis in a Japanese population: Role of cigarette smoking. Int J Cardiol 2000; 72: 121-126.
3. Fujiwara H. Anti-smoking declaration: A message from the Japanese Circulation Society: The Anti-smoking Committee, Japanese Circulation Society. Circ J 2003; 67: 1-2.
4. Smith SC Jr, Milani RV, Arnett DK, Crouse JR 3rd, McDermott MM, Ridker PM, et al. American Heart Association: Atherosclerotic Vascular Disease Conference: Writing Group II: Risk factors. Circulation 2004; 109: 2613-2616.
5. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-126.
6. Glass CK, Witztum JL. Atheroslcerosis: The road ahead. Cell 2001; 104: 503-516.
7. Libby P, Ridker PM, Maser A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
8. Sugiyama S, Kugiyama K, Ohgushi M, Fujimoto K, Yasue H. Lyso-phosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries: Role of protein kinase C. Circ Res 1994; 74: 565 - 575.
9. Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, et al. American Heart Association: Atherosclerotic Vascular Disease Conference: Writing Group III: Pathophysiology. Circulation 2004; 109: 2617-2625.
10. Kugiyama K, Yasue H, Ohgushi M, Motoyama T, Kawano H, Inobe Y, et al. Deficiency in nitric oxide bioactivity in epicardial coronary arteries of smokers. J Am Coll Cardiol 1996; 28: 1161-1167.
11. Sumida H, Watanabe H, Kugiyama K, Ohgushi M, Matsumura T, Yasue H. Does passive smoking impair endothelium-dependent coronary arterial dilation in women? J Am Coll Cardiol 1998; 31: 811-815.
12. Otsuka R, Watanabe H, Hirata K, Tokai K, Muro T, Yoshiyama M, et al. Acute effects of passive smoking on the coronary circulation in healthy young adults. JAMA 2001; 286: 436-441.
13. Barua RS, Ambrose JA, Eales-Reynolds LJ, DeVoe MC, Zervas JG, Saha DC. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation. Circulation 2001; 104: 1905-1910.
14. Motoyama Y, Kawano H, Kugiyama K, Hirashima O, Ohgushi M, Yoshimura M, et al. Endothelium-dependent vasodilation in the brachial artery is impaired in smokers: Effect of vitamin C. Am J Physiol 1998; 273: H1644-H1650.
15. Hirai N, Kawano H, Hirashima O, MotoyamaT, Moriyama Y, Sakamoto T, et al. Insulin resistance and endothelial dysfunction in smokers: Effects of vitamin C. Am J Physiol 2000; 279: H1172-H1178.
16. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: Evidence for a dysfunctional nitric oxide synthase. Circ Res 2000; 86: E36-E41.
17. Soeki T, Tamura Y, Shinohara H, Sakabe K, Onose Y, Fukuda N. Elevated concentration of soluble vascular endothelial cadherin is associated with coronary atherosclerosis. Circ J 2004; 68: 1-5.
18. Esen AM, Barutch I, Acar M, Degirmenci B, Kaya D, Turkmen M, et al. Effect of smoking on endothelial function and wall thickness of brachial artery. Circ J 2004; 68: 1123-1126.
19. Murohara T, Kugiyama K, Ohgushi M, Sugiyama S, Yasue H. Cigarette smoke extract contracts isolated porcine coronary arteries by superoxide anion-mediated degradation of EDRF. Am J Physiol 1994; 266: H874-H880.
20. Ohta Y, Kugiyama K, Sugiyama S, Ohgushi M, Yasue H. Impairment of endothelium-dependent relaxation of rabbit aortas by cigarette smoke extract: Role of free radicals and attenuation by captopril. Atherosclerosis 1997; 131: 195-202.
21. Barua RS, Ambrose JA, Srivastava S, DeVoe MC, Eales-Reynolds LJ. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: An in vitro demonstration in human coronary artery endothelial cells. Circulation 2003; 107: 2342-2347.
22. Guthikonda S, Sinkey C, Barenz T, Haynes WG. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 2003; 107: 416-421.
23. McWhorter VC, Ford LC, Butch AW. Analytical performance of the Synchron LX20 Pro, BN trade mark II and IMMAGE high sensitivity C-reactive protein assays and concordance in cardiovascular risk stratification. Clin Chim Acta 2004; 347: 71-79.
24. Nakajima K, Saito K, Tamura A, Suzuki M, Nakano T, Tamura M, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal antiapoB-100 and antiapoA-1 immunoaffinity mixed gels. Clin Chim Acta 1993; 223: 53-71.
25. Kasai T, Motoi S. Principles of analysis by the automated coagulation analyzer CA-6000. Sysmex J Int 1997; 7: 43-47.
26. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86: 1243-1254.
27. Rohde LP, Hennekens CH, Ridker PM. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 1999; 84: 1018-1022.
28. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003; 138: 891-897.
29. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-137.
30. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004; 279: 48487-48490.
31. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: Risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6-11.
32. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109: IV6-IV19.
33. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003; 91: 7A-11A.
34. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999; 85: 753-766.
35. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14,719 initially healthy American women. Circulation 2003; 107: 391-397.
36. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-1454.
37. Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 2005; 28: 690-693.
38. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000; 181: S462-S472.
39. Doi H, Kugiyama K, Oka H, Sugiyama S, Ogata N, Koide SI, et al. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 2000; 102: 670-676.
40. Doi H, Kugiyama K, Ohgushi M, Sugiyama S, Matsumura T, Ohta Y, et al. Membrane active lipids in remnant lipoproteins cause impairment of endothelium-dependent vasorelaxation. Arterioscler Thromb Vasc Biol 1999; 19: 1918-1924.
41. Kugiyama K, Motoyama T, Doi H, Kawano H, Hirai N, Soejima H, et al. Improvement of endothelial vasomotor dysfunction by treatment with alpha-tocopherol in patients with high remnant lipoproteins levels. J Am Coll Cardiol 1999; 33: 1512-1518.
42. Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999; 99: 2858-2860.
43. Twickler TB, Dallinga-Thie GM, Cohn JS, Chapman MJ. Elevated remnant-like particle cholesterol concentration: A characteristic feature of the atherogenic lipoprotein phenotype. Circulation 2004; 109: 1918-1925.
44. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: Role in inflammatory thrombocytosis. Blood 2001; 98: 2720-2725.
45. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: A systematic review. JAMA2003; 290: 86-97.
46. Monaco C, Rossi E, Milazzo D, Citterio F, Ginnetti F, D'Onofrio G, et al. Persistent systemic inflammation in unstable angina is largely unrelated to the atherothrombotic burden. J Am Coll Cardiol 2005; 45: 238-243.
47. Azar RR, Aoun G, Fram DB, Waters DD, Wu AH, Kiernan FJ. Relation of C-reactive protein to extent and severity of coronary narrowing in patients with stable angina pectoris or abnormal exercise tests. Am J Cardiol 2000; 86: 205-207.
48. Caruso C, Lio D, Cavallone L, Franceschi C. Aging, longevity, in-flammation, and cancer. Ann NY Acad Sci 2004; 1028: 1-13.
49. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci USA 2003; 100: 9090-9095.
50. Bruunsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am 2003; 23: 15-39.